Analysts Set Viking Therapeutics, Inc. (NASDAQ:VKTX) Price Target at $89.36

Viking Therapeutics, Inc. (NASDAQ:VKTX) has earned a consensus recommendation of “Moderate Buy” from the thirteen research firms that are covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation, six have given a buy recommendation and three have issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $87.80.

VKTX has been the topic of several recent analyst reports. Canaccord Genuity Group increased their target price on shares of Viking Therapeutics from $106.00 to $107.00 and gave the stock a “buy” rating in a research note on Wednesday, November 12th. JPMorgan Chase & Co. lowered their price target on Viking Therapeutics from $80.00 to $75.00 and set an “overweight” rating on the stock in a research report on Friday, October 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Viking Therapeutics in a report on Wednesday, January 21st. Cantor Fitzgerald set a $105.00 target price on Viking Therapeutics in a research note on Thursday, October 23rd. Finally, Morgan Stanley reiterated an “overweight” rating and set a $99.00 target price on shares of Viking Therapeutics in a research report on Thursday.

Key Headlines Impacting Viking Therapeutics

Here are the key news stories impacting Viking Therapeutics this week:

• Positive Sentiment: Company fast‑tracked oral VK2735 into Phase III obesity trials, a material clinical de‑risking and commercialization signal that prompted a sharp rally in headlines and investor enthusiasm. Viking Therapeutics (VKTX) Is Up 16.0% After Fast-Tracking VK2735 Into Phase III Trials – Has The Bull Case Changed?
• Positive Sentiment: Management outlined dual Phase III obesity programs and maintenance regimens for VK2735, giving investors a clearer late‑stage development plan and multiple potential commercialization paths. Viking Therapeutics outlines dual Phase III obesity programs while advancing oral VK2735 and maintenance regimens
• Neutral Sentiment: Coverage and valuation checks are proliferating (analysis pieces and retrospectives on historical returns), which can broaden investor interest but don’t change clinical or financial fundamentals. Viking Therapeutics (VKTX) Valuation Check After Q4 2025 Earnings And Obesity Pipeline Progress
• Neutral Sentiment: Media and transcript coverage (earnings call transcripts, long‑term return pieces) are available for deeper diligence but are informational rather than new catalysts. Viking Therapeutics, Inc. (VKTX) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Q4 results showed a wider‑than‑expected loss (EPS miss) which raises near‑term cash‑burn and financing questions; that financial disappointment likely prompted profit‑taking after the clinical rally. VKTX Posts Wider-Than-Expected Loss in Q4, Stock Up on Pipeline Updates
• Negative Sentiment: Analysts (HC Wainwright) continue to model losses for upcoming quarters/years, reinforcing the expectation that Viking will need to fund late‑stage development — a potential dilution risk that can cap upside until Phase III readouts or financing clarity. MarketBeat VKTX overview / analyst note

Viking Therapeutics Price Performance

Shares of NASDAQ VKTX opened at $29.00 on Wednesday. The stock has a market capitalization of $3.35 billion, a price-to-earnings ratio of -9.12 and a beta of 0.75. The firm’s 50 day simple moving average is $33.13 and its 200-day simple moving average is $32.58. Viking Therapeutics has a 12 month low of $18.92 and a 12 month high of $43.15.

Viking Therapeutics (NASDAQ:VKTX) last posted its earnings results on Wednesday, February 11th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.49). During the same quarter in the previous year, the business posted ($0.32) EPS. Analysts anticipate that Viking Therapeutics will post -1.56 earnings per share for the current fiscal year.

Insider Activity at Viking Therapeutics

In related news, CEO Brian Lian sold 233,409 shares of the company’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $32.96, for a total transaction of $7,693,160.64. Following the completion of the transaction, the chief executive officer owned 2,499,291 shares in the company, valued at $82,376,631.36. This represents a 8.54% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Marianna Mancini sold 57,661 shares of the firm’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $32.98, for a total transaction of $1,901,659.78. Following the completion of the transaction, the chief operating officer directly owned 409,190 shares in the company, valued at $13,495,086.20. This represents a 12.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 364,731 shares of company stock valued at $12,053,627. 4.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Viking Therapeutics

A number of hedge funds have recently made changes to their positions in VKTX. Jump Financial LLC purchased a new stake in Viking Therapeutics in the second quarter valued at $12,201,000. Norges Bank purchased a new position in shares of Viking Therapeutics during the 2nd quarter worth $46,846,000. RFG Advisory LLC increased its position in shares of Viking Therapeutics by 84.8% during the 3rd quarter. RFG Advisory LLC now owns 120,214 shares of the biotechnology company’s stock worth $3,159,000 after purchasing an additional 55,175 shares during the last quarter. Marex Group plc acquired a new stake in shares of Viking Therapeutics during the 2nd quarter worth about $983,000. Finally, Bryce Point Capital LLC purchased a new stake in Viking Therapeutics in the 2nd quarter valued at about $499,000. Institutional investors and hedge funds own 76.03% of the company’s stock.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Headquartered in San Diego, California, the company’s pipeline leverages small-molecule approaches to target hormone signaling pathways implicated in conditions such as non‐alcoholic steatohepatitis (NASH), dyslipidemia, type 2 diabetes and muscle wasting disorders.

The company’s lead programs include VK2809, a thyroid hormone receptor‐beta agonist designed to reduce liver fat and improve lipid profiles in patients with NASH and dyslipidemia, and VK5211, a selective androgen receptor modulator (SARM) aimed at enhancing muscle mass and function in individuals with muscle wasting conditions.